Clario Partners With Emsere, Extends Ophthalmic Medical Imaging Capabilities
New collaboration offers end-to-end solution, supplying and training sites on ophthalmic medical imaging equipment.
Clario has announced a strategic partnership with medical equipment supplier for clinical trials, Emsere. This collaboration will provide a comprehensive, end-to-end solution that streamlines the execution of clinical trials requiring ophthalmic medical imaging and equipment.1
A key in this new partnership is Emsere’s global presence, allowing the new solution to reach sites that lack the necessary equipment to meet study protocols.
"We're thrilled to partner with Emsere in pursuit of our mutual goals. This collaboration underscores our shared commitment to providing a solution tailored to meet the diverse needs in clinical trials. Our objective is to streamline every aspect of the process. By leveraging our collective expertise, we'll deliver solutions that simplify image capture, enhance quality assessment, and optimize analysis procedures,” Joyce Suhy, PhD, executive vice president, medical imaging and specialty solutions, Clario said in a press release. “Furthermore, we're mindful of the challenges encountered by trial sites that lack the equipment to meet protocol requirements. This solution includes support and strategies to address these challenges effectively."
Earlier in March 2024, Clario announced a strategic partnership with the Cleveland Clinic’s Cole Eye Institute, bringing Cleveland Clinic’s ophthalmology imaging expertise and artificial intelligence-driven analysis platforms together with Clario’s vendor-agnostic image management system.2
The driving force behind Clario’s experience in ophthalmology is its clinical trial management platform, which enables visualization and analysis of images from all ophthalmic modalities including OCT/OCTA, color fundus photography, fluorescein angiography, and others across all major indications.
References
1. Clario partners with Emsere to extend ophthalmic medical imaging capabilities for clinical trials. News release. May 21, 2024. Accessed May 24, 2024. https://www.prnewswire.com/news-releases/clario-partners-with-emsere-to-extend-ophthalmic-medical-imaging-capabilities-for-clinical-trials-302143501.html
2. Clario and Cleveland Clinic’s Cole Eye Institute announce strategic partnership to provide new ophthalmology offerings for clinical trials. News release. March 12, 2024. Accessed May 24, 2024. https://clario.com/about/newsroom/clario-and-cleveland-clinics-cole-eye-institute-announce-strategic-partnership-to-provide-new-ophthalmology-offerings-for-clinical-trials/
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
